LumiraDx Limited (LMDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LMDX Stock Price Chart Interactive Chart >
LMDX Price/Volume Stats
|Current price||$3.72||52-week high||$11.09|
|Prev. close||$3.86||52-week low||$3.40|
|Day high||$3.95||Avg. volume||60,381|
|50-day MA||$5.53||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||168.29M|
LumiraDx Limited (LMDX) Company Bio
LumiraDx Limited operates as a point of care diagnostic company. It focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. The company was formerly known as Point of Care Testing Limited and changed its name to LumiraDx Ltd in January 2018. LumiraDx Limited was incorporated in 2002 and is based in London, the United Kingdom.
Most Popular Stories View All
LMDX Latest News Stream
|Loading, please wait...|
LMDX Latest Social Stream
View Full LMDX Social Stream
Latest LMDX News From Around the Web
Below are the latest news stories about LumiraDx Ltd that investors may wish to consider to help them evaluate LMDX as an investment opportunity.
The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how Community Health Systems (CYH) and LumiraDx Limited (LMDX) have performed compared to their sector so far this year.
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live Omicron virus demonstrated that the LumiraDx SARS-CoV-2 Antigen test detects the Omicron variant with comparable sensitivity to other variants. In the original U.S. Food and Drug Administration ("FDA") Emergency Use Authorization ("EUA") clini
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking. The LumiraDx CRP Test is a small, portable, fully automated, microfluidic immunoassay test used for the quantitative determination of C-reactive protein with results within four minutes. The measurement of CRP provides important information for the detection and evaluation of infection, and inflammation. In patients with respiratory infection sy
LMDX Price Returns